Next Generation Bispecific Antibody Platform
Our next generation bispecific antibody platform is supporting the expansion of additional candidates for inflammatory diseases and oncology
Bispecific antibodies can engage two independent pathways involved in controlling immune reactions and combining these into one molecule can result in stronger activity than a combination of the independent antibodies.
Targets are being selected based on new science as well as their compatibility to be used in bispecific antibody formats with Celldex’s existing antibody programs. Lead targets in development are emerging as important pathways controlling inflammatory diseases or immunity to tumors.